Review Article
Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus
Table 6
The effect of Len/Dex treatment according to prior response to thalidomide. Adapted from Wang et al. [19].
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1Sensitive: patients with stable disease or better who did not progress while on thalidomide. 2Relapsed: patients with stable disease or better who progressed while on thalidomide. 3Resistant: patients who progressed on thalidomide but never responded to thalidomide. Len/Dex: lenalidomide combined with dexamethasone; PR: partial response; PFS: progression-free survival; NE: not estimable. |